Human endometrial carcinomas serially transplanted in nude mice and established in continuous cell lines.

Détails

ID Serval
serval:BIB_3F0E38799DC4
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Human endometrial carcinomas serially transplanted in nude mice and established in continuous cell lines.
Périodique
International Journal of Cancer
Auteur⸱e⸱s
Merenda C., Sordat B., Mach J.P., Carrel S.
ISSN
0020-7136 (Print)
ISSN-L
0020-7136
Statut éditorial
Publié
Date de publication
1975
Volume
16
Numéro
4
Pages
559-570
Langue
anglais
Résumé
Three out of five human endometrial carcinomas were successfully grafted into nude mice (BALB/c/nu/nu). Two of these tumors could be maintained by serial transplantation. The morphological characteristics displayed by the grafted tumors were comparable to those of the original carcinomas. Permanent cell lines were established from these two tumors. Reinjection of cells grown in vitro into nude mice produced nodules of identical histology as compared to original solid transplants. The influence of medroxyprogesterone acetate on tumor growth in vivo and cell proliferation in vitro was studied. This hormonal treatment did not produce any significant effect on tumor cells, either in vitro or in vivo, for the two endometrial carcinomas. After medroxyprogesterone administration, a slight but non-significant growth inhibition of the tumor cells in vitro was observed and the tumor transplants in vivo did not appear to be influenced. The experiments illustrate the possible use of this model for testing potential anti-cancer agents.
Mots-clé
Adenocarcinoma/pathology, Animals, Cell Line, Cell Transformation, Neoplastic/drug effects, Female, Humans, Medroxyprogesterone/pharmacology, Mice, Mice, Inbred BALB C, Mice, Nude, Neoplasm Transplantation, Neoplasms, Experimental, Stimulation, Chemical, Transplantation, Heterologous, Uterine Neoplasms/pathology
Pubmed
Web of science
Création de la notice
25/04/2013 10:44
Dernière modification de la notice
20/08/2019 14:36
Données d'usage